AU2002218751A1 - Stable radiopharmaceutical compositions - Google Patents

Stable radiopharmaceutical compositions

Info

Publication number
AU2002218751A1
AU2002218751A1 AU2002218751A AU1875102A AU2002218751A1 AU 2002218751 A1 AU2002218751 A1 AU 2002218751A1 AU 2002218751 A AU2002218751 A AU 2002218751A AU 1875102 A AU1875102 A AU 1875102A AU 2002218751 A1 AU2002218751 A1 AU 2002218751A1
Authority
AU
Australia
Prior art keywords
radiopharmaceutical compositions
stable radiopharmaceutical
stable
compositions
radiopharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218751A
Other languages
English (en)
Inventor
John A Barrett
Alan P. Carpenter Jr.
Shuang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2002218751A1 publication Critical patent/AU2002218751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002218751A 2000-07-06 2001-07-05 Stable radiopharmaceutical compositions Abandoned AU2002218751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639600P 2000-07-06 2000-07-06
US60/216,396 2000-07-06
PCT/US2001/021261 WO2002004030A2 (fr) 2000-07-06 2001-07-05 Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions

Publications (1)

Publication Number Publication Date
AU2002218751A1 true AU2002218751A1 (en) 2002-01-21

Family

ID=22806902

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218751A Abandoned AU2002218751A1 (en) 2000-07-06 2001-07-05 Stable radiopharmaceutical compositions

Country Status (5)

Country Link
US (1) US20020122768A1 (fr)
EP (1) EP1311301A2 (fr)
AU (1) AU2002218751A1 (fr)
CA (1) CA2413538A1 (fr)
WO (1) WO2002004030A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
JP2002532440A (ja) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CA2412849A1 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
CA2413328A1 (fr) * 2000-06-21 2001-12-27 Milind Rajopadhye Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
AU7296501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
BR0207315A (pt) * 2001-02-26 2004-02-10 Bristol Myers Squibb Pharma Co Análogos de ácido ascórbico para metalorradiofármacos
US20030198593A1 (en) * 2002-04-15 2003-10-23 Frank R. Keith Radioprotectants for radiopharmaceutical formulations
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
ES2347535T3 (es) * 2002-11-05 2010-11-02 Ion Beam Applications S.A. Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol.
CA2525396A1 (fr) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Composes de l'antagoniste du recepteur de la vitronectine et leur utilisation dans la preparation de produits radio pharmaceutiques
BRPI0412824A (pt) * 2003-07-24 2006-09-26 Bracco Imaging Spa composições radiofarmacêuticas estáveis e métodos para suas preparações
WO2005032599A1 (fr) * 2003-09-30 2005-04-14 Semafore Pharmaceuticals Inc. Squelettes a base de chelates utilises pour le ciblage de tumeurs
WO2007115131A2 (fr) * 2006-03-29 2007-10-11 Guilford F Timothy Combinaison de glutathion réduit liposomique et de 1-arginine, avec un ou plusieurs autres ingrédients, pouvant être administrée par plusieurs voies, permettant d'inverser et de prévenir l'obésité et de stimuler la biogenèse mitochondriale
GB0514087D0 (en) 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
CA2634666C (fr) * 2005-12-22 2015-05-26 Duke University Compositions stabilisees et procedes permettant de radiomarquer des produits pharmaceutiques avec des emetteurs de particules alpha
JP5297815B2 (ja) * 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8609707B2 (en) 2010-01-28 2013-12-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CN101865894B (zh) * 2010-06-28 2012-11-21 江苏奥赛康药业股份有限公司 一种奈达铂冻干粉针剂的杂质检测方法
CA2840409A1 (fr) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Utilisation de sortases pour installer des attaches de chimie click pour la ligature de proteine
WO2013093099A1 (fr) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilisation de produits radiopharmaceutiques peptidiques à l'aide de l'acide urique ou des dérivés de celui-ci
FR2995536B1 (fr) * 2012-09-17 2014-09-26 Lemer Prot Anti X Par Abreviation Soc Lemer Pax Unite medicale pour l'injection de rubidium 82 a un patient
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
WO2015073746A2 (fr) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research Marquage de protéines au 18f, faisant appel à des sortases
CN111175423B (zh) * 2016-12-23 2022-07-12 江苏奥赛康药业有限公司 一种奈达铂的分析方法
US11351276B2 (en) * 2018-06-22 2022-06-07 Jubilant Draximage Inc. Radiopharmaceutical compositions of radioactive halogenated benzylguanidine
WO2021087568A1 (fr) * 2019-11-08 2021-05-14 The University Of Queensland Ligands de ciblage radiomarqués
IL301868A (en) * 2020-10-22 2023-06-01 Nihon Mediphysics Co Ltd A method for preparing a radioactive zirconium complex
CN112546247A (zh) * 2020-12-03 2021-03-26 西南医科大学附属医院 多羟基苯酚类化合物的应用、放射性药物组合物及制法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3780820D1 (fr) * 1987-10-30 1992-09-03 Sorin Biomedica S.P.A., Saluggia, Vercelli, It
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
WO1997028181A2 (fr) * 1996-02-02 1997-08-07 Rhomed Incorporated Stabilisation apres marquage de proteines et de peptides radiomarquees
BR9909420A (pt) * 1998-03-31 2001-09-25 Du Pont Pharm Co Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico
GB0015242D0 (en) * 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals

Also Published As

Publication number Publication date
EP1311301A2 (fr) 2003-05-21
WO2002004030A2 (fr) 2002-01-17
WO2002004030A3 (fr) 2003-02-27
US20020122768A1 (en) 2002-09-05
CA2413538A1 (fr) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2002218751A1 (en) Stable radiopharmaceutical compositions
AU2001292783A1 (en) Antireflective composition
AU781269C (en) Pharmaceutical compositions
AU2001282877A1 (en) Cosmetic compositions
AU2001233691A1 (en) Antiperspirant compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001282617A1 (en) Compositions for external preparations
AU2001265919A1 (en) Cosmetic compositions
AUPQ875700A0 (en) Combination compositions
AU2001285790A1 (en) Antiperspirant compositions
AU2001241098A1 (en) Composition
GB0019651D0 (en) Compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU2002210433A1 (en) Dental compositions
AU2681500A (en) Rapidly-soluble compositions
AU2001270235A1 (en) Oral compositions
AU5085300A (en) Compositions
AU2001275201A1 (en) Acne-treating composition
AU2001214419A1 (en) Fragrance compositions
AU2001287852A1 (en) Composition
AU2002228899A1 (en) Fragrance enhancing compositions with non-polycyclics
AU2001235764A1 (en) Compositions
AU2001256202A1 (en) Cosmetic compositions
AU2000274826A1 (en) Cosmetic compositions